Výsledky vyhledávání - "FITZGERALD PJ"

Akademický článek

Beta blockers, norepinephrine, and cancer: an epidemiological viewpoint

Autor: Fitzgerald PJ

Publikováno v: Clinical Epidemiology, Vol 2012, Iss default, Pp 151-156 (2012)

Paul J FitzgeraldThe Zanvyl Krieger Mind/Brain Institute, Solomon H Snyder Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USAAbstract: There is growing evidence that the neurotransmitter norepinephrine (NE) and its sister molecu

Externí odkaz: https://doaj.org/article/a91b54ad729642f8b6adb6de1bb2e79b

Zobrazit plný text záznamu

Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease

Autor: Gerstein, HC, Ratner, RE, Cannon, CP, Serruys, PWJC (Patrick), Garcia Garcia, Hector, Es, Gerrit-anne, Kolatkar, NS, Kravitz, BG, Miller, DM, Huang, C, Fitzgerald, PJ, Nesto, RW

Publikováno v: Circulation, 121(10), 1176-1187. Lippincott Williams & Wilkins

Background-Rosiglitazone has several properties that may affect progression of atherosclerosis. The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History (APPROACH) study was

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::c7aeb76467c91e11c8781f0aa9e68ad0
https://pure.eur.nl/en/publications/bd6f9f99-b81d-44cf-b908-66b8a07f9754

Zobrazit plný text záznamu

A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial

Autor: Chevalier, B, Di Mario, C, Neumann, Fj, Ribichini, Flavio Luciano, Urban, P, Popma, Jj, Fitzgerald, Pj, Cutlip, De, Williams, Do, Ormiston, J, Grube, E, Whitbourn, R, Schwartz, Lb, Investigators, ZoMaxx I.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1943::c656ad16acbf30b1961526175f677662
http://hdl.handle.net/11562/339654

Zobrazit plný text záznamu

From vulnerable plaque to vulnerable patient - A call for new definitions and risk assessment strategies: Part I

Autor: Naghavi, M Libby, P Falk, E Casscells, SW Litovsky, S and Rumberger, J Badimon, JJ Stefanadis, C Moreno, P and Pasterkamp, G Fayad, Z Stone, PH Waxman, S Raggi, P and Madjid, M Zarrabi, A Burke, A Yuan, C Fitzgerald, PJ and Siscovick, DS de Korte, CL Aikawa, M Airaksinen, KEJ and Assmann, G Becker, CR Chesebro, JH Farb, A Galis, ZS and Jackson, C Jang, IK Koenig, W Lodder, RA March, K and Demirovic, J Navab, M Priori, SG Rekhter, MD Bahr, R and Grundy, SM Mehran, R Colombo, A Boerwinkle, E and Ballantyne, C Insull, W Schwartz, RS Vogel, R Serruys, PW Hansson, GK Faxon, DP Kaul, S Drexler, H and Greenland, P Muller, JE Virmani, R Ridker, PM Zipes, DP and Shah, PK Willerson, JT

Atherosclerotic cardiovascular disease results in >19 million deaths annually, and coronary heart disease accounts for the majority of this toll. Despite major advances in treatment of coronary heart disease patients, a large number of victims of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::7ca749f2cb15fcb55b7de67a19381095
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3084498

Zobrazit plný text záznamu